Zevra Therapeutics (ZVRA)

Executive Summary

Zevra Therapeutics is a public biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases. The company has two approved products, MIPLYFFA® and OLPRUVA®, which generate revenue and support its pipeline. Zevra's clinical programs target high-unmet-need indications, including idiopathic hypersomnia and various metabolic disorders. The pipeline features Serdexmethylphenidate (Phase 2, idiopathic hypersomnia, study completed), sodium phenylbutyrate (Phase 1/2 for combined D,L-2-hydroxyglutaric aciduria and medium-chain acyl-CoA dehydrogenase deficiency), and KP415 (Phase 3, ADHD, completed). Leveraging a data-driven regulatory approach, Zevra aims to accelerate development timelines and address significant patient needs. The company's near-term focus is on advancing its pipeline and exploring label expansion opportunities for its marketed products. With a strong balance sheet and commercial infrastructure, Zevra is well-positioned to execute its strategy. However, the pipeline is still early-stage, and key data readouts are needed to validate clinical potential. The stock's valuation reflects optimism around upcoming catalysts but also risks associated with clinical and regulatory outcomes.

Upcoming Catalysts (preview)

• Q4 2026Serdexmethylphenidate Phase 2 topline results for idiopathic hypersomnia60% success
• H2 2027Sodium phenylbutyrate interim Phase 2 data for medium-chain acyl-CoA dehydrogenase deficiency35% success
• H1 2027Initiation of Phase 3 trial for Serdexmethylphenidate in idiopathic hypersomnia70% success